Join our community of traders FOR FREE!

  • Learn
  • Improve yourself
  • Get Rewards
Learn More

Publicis Groupe SA reduced its annual sales projection after the revenue it reported over the third quarter missed analysts forecasts, as the company has been facing difficulties due to a failed merger with Omnicom Group Inc.

The companys Chief Executive Officer, Maurice Levy, said in an interview for the Wall Street Journal: “Performances don’t live up to what the market and we ourselves were expecting. We now hope for a much better 2015. (…) We are at the end of a cycle during which our attention wasn’t focused enough on taking short-term actions and on growth.” As reported by Reuters, Mr. Levy also added: “There are a number of factors behind this, mainly the fact that management was too focused on other plans and not enough on the short-term performance and growth.”

Publicis reported that its full-year organic sales excluding acquisitions are expected to be similar to the 1.5% growth, reported during the first nine months of the fiscal year. In comparison, the companys previous forecast, made in February, pointed to a 4% growth.

Publicis said that its total revenue totalled €1.7 billion ($2.1 billion) over the last three months ended September 30th. The France-based company also revealed that its organic sales excluding currency flotations, acquisitions and disposals over the period increased by only 1% due to slower growth in Europe and emerging markets.

In a statement posted in September this year, the company reaffirmed its targets until 2018 and revealed that it is not planning to present a special strategy to investors in October. Publicis has been dealing with some hard time after its $35-billion merger with Omnicom Group failed in May, as the executives failed to reach an agreement over the management of the combined company.

Publicis Groupe SA lost 3.10% to trade at €54.89 per share by 12:42 GMT, marking a one-year loss of 13.60%. The company is valued at €11.83 billion. According to the Financial Times, the 23 analysts offering 12-month price targets for Publicis Groupe SA have a median target of €65.00, with a high estimate of €75.30 and a low estimate of €52.00. The median estimate represents a 21.38% increase from the last price of €53.55.

TradingPedia.com is a financial media specialized in providing daily news and education covering Forex, equities and commodities. Our academies for traders cover Forex, Price Action and Social Trading.

Related News

  • Microsoft planning to lay off thousands of employees across divisions, media reports sayMicrosoft planning to lay off thousands of employees across divisions, media reports say A number of media reports stated on Tuesday Microsoft Corp (MSFT) intended to cut thousands of job positions, with roles in divisions such as human resources and engineering expected to be affected.Such a move by Microsoft could […]
  • USD/ZAR: Rand extends pullback from 3-month troughUSD/ZAR: Rand extends pullback from 3-month trough The South African Rand extended a pullback from recent three-month low against the US Dollar on Friday on prospects of the Federal Reserve keeping borrowing costs without change at its September policy meeting.Although the US Dollar […]
  • Brazil coffee harvest acceleratesBrazil coffee harvest accelerates Coffee harvest in the worlds biggest producer and exporter, Brazil, is going to pick up the pace after it stalled due to unfavorable wet weather. According to a Somar Meteoroligia report, growing areas will get dry weather for a long period […]
  • Soft futures mixed for a second daySoft futures mixed for a second day Cotton futures extended gains from the previous session and hit a two-week high. On the ICE Futures U.S. Exchange, cotton futures for July delivery traded at $0.8318 a pound at 12:48 GMT, up 0.99% for the day. It rose by 1.5% earlier and hit […]
  • Pfizer Inc.’s share price down, to buy rights to a cancer drug of Merck at the price of $850 millionPfizer Inc.’s share price down, to buy rights to a cancer drug of Merck at the price of $850 million Pfizer Inc. is to pay $850 million for rights to a cancer drug, developed by Merck KGaA. The deal is to grant Pfizer the opportunity to get an experimental treatment such as the one it looked for when it made its takeover bid for Astrazeneca […]
  • Forex Market: GBP/NZD daily forecastForex Market: GBP/NZD daily forecast During yesterday’s trading session GBP/NZD traded within the range of 1.9535-1.9668 and closed at 1.9586.At 6:51 GMT today GBP/NZD was losing 0.13% for the day to trade at 1.9529. The pair touched a daily low at 1.9518 at 6:12 […]